Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luveltamab tazevibulin - Sutro Biopharma

Next Previous
Drug Profile

Luveltamab tazevibulin - Sutro Biopharma

Alternative Names: anti-FolRa ADC STRO-002; anti-FolRalpha ADC STRO-002; FolR-alpha-ADC-Sutro-Biopharma; Luvelta; STRO-002

Latest Information Update: 04 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sutro Biopharma
  • Developer Gynecologic Oncology Group; Sutro Biopharma; Tasly Biopharmaceuticals
  • Class Amides; Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Indoles
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 24 Aug 2025 Sutro Biopharma terminates phase I/II REFRαME P1 trial in Acute myeloid leukemia (In neonates, In infants, In children, Second-line or greater therapy) in Austria, Canada, Denmark, France, Germany, Italy, Netherlands, Spain and USA (IV) (NCT06679582)
  • 30 May 2025 Efficacy data from a compassionate use programm presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 15 Mar 2025 Updated adverse events and efficacy data from the phase II/III REFRaME-O1 trial in Ovarian cancer released by Sutro Biopharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top